

H1 Earnings 2025

September 25, 2025

2025





H1 Group earnings





Highlights

- Workforce restructuring at the pharmacy business
- Business activities of INPS sold
- Cegedim Group shares transferred to trading on Euronext Growth
- SBTi validates Cegedim's decarbonization targets
- Credit facility converted to a sustainability-linked loan





The big picture

Revenue

€322.5m +€3.5m

+1.1% reported

+2.8% like-for-like

Employees

6 605

(2.4)%

(164)

Adjusted Operating Income

€18.5m

+78.4%

+8.2m

Operating FCF

56.6m€

+€34.4m

Exceptional items

€(9.0)m | €(2.6)m

H1 2025 | H1 2024

Net debt

Excl. IFRS 16

€182m

(15.0)%

(32.0)m€

H1 2025 vs H1 2024






P&L

	in million euros	H1 2025	H1 2024	Change %	Change€
	Revenue	322.5	319.0	+1.1%	+3.5
	Purchase used	(13.3)	(14.0)	(5.0)%	+0.7
	External expenses	(67.7)	(72.7)	(6.9)%	+5.0
	Payroll costs	(177.9)	(173.2)	+2.7 %	(4.7)
	Others	(2.4)	(6.8)	+35.3 %	+4.4
	Adjusted EBITDA	61.2	52.2	+17.2%	+9.0
	Adjusted EBITDA margin	19.0%	16.4%	+261 bps	-
	Other items affecting operating income	1.6	-		
	Recurring EBITDA	59.6	52.2	+14.2%	+7.4
	D&A	(42.7)	(41.9)	+2.1 %	(0.8)
	Adjusted Operating Income (Adj.EBIT)	18.5	10.3	+78.4%	+8.2
	Adjusted Operating Income margin	5.7%	3.2%	+248 bps	-
	Recurring Operating Income	16.9	10.3	+63.2%	+6.6
	Non-Recurring Operating Income and expenses	(7.4)	(2.6)	+183.3%	(4.8)
	Operating income	9.5	7.7	+22.4%	+1.8
	Financial results	(8.3)	(5.0)	+65.3%	(3.3)
	Total Tax	(1.0)	(2.9)	(66.8)%	+1.9
	Share of profit (loss)for the period of equity method companies	(0.1)	0.1	n.S	(0.2)
	Non-controlling interests	(1.1)	(0.7)	+47.8%	(0.3)
cegedim	Net income, Group share	1.2	0.6	+87.5%	+0.6




R&D Investment

Capitalized R&D



D&A of R&D



Impact on Adjusted Operating Income (Adj.EBIT)









Payroll costs


Payroll costs



Headcount



Offshore







Free Cash Flow

in million of euros	H1 2025	H1 2024
Net income, Group share	0.1	(0.1)
Depreciation and amortization expenses and provisions	49.1	40.5
Cost of net financial debt	8.3	5.0
Share of earnings from equity method companies; tax expenses	0.2	1.6
Operating Cash flow before cost of net financial debt and taxes	57.7	47.1
Tax paid	+1.3	(11.6)
Change in working capital requirements from operations	(2.4)	(13.2)
Cash flow generated from operating activities (A)	56.6	22.2
Acquisition of intangible assets	(25.2)	(29.9)
Acquisition of tangible assets	(12.5)	(15.9)
Impact of changes in consolidation scope	(0.5)	(35.5)
Others	+1.9	+4.7
Net Cash flow generated by investment operations (B)	(36.2)	(76.6)
Repayment of lease liabilities	(8.0)	(8.2)
Loan	-	+55.0
Others	(11.8)	(3.0)
Net cash flow generated by financing operations (C)	(19.9)	43.9
Change in cash (A+B+C)	+0.6	(10.5)

Net Debt H1 2024 €214m FY 2024 €185m H1 2025 €182m





Financing

June,30 2025				
Drawn	Total amount	Maturity		
€177.0m	€177.0m	2031		
€47.7m	€47.7m	2031		
-	€50.0m	2029		
	€177.0m	Drawn Total amount €177.0m €177.0m €47.7m		





Balance sheet

Assets		
in million of euros	30/06/2025	31/12/2024
Goodwill	235.2	235.7
Intangible assets	190.8	191.4
Tangible assets	145.4	144.7
Financial assets	23.6	20.0
Other non-current assets	52.5	32.0
Trade receivables, short- term portion	180.3	186.0
Other current assets	106.7	127.5
Cash & cash equivalents	49.9	49.6
Total Asset	984.4	986.9

Shareholders equity & liabilities						
in million of euros	30/06/2025	31/12/2024				
Shareholder equity	282.0	282.5				
Long-term financial debt	219.0	223.8				
Other non-current liabilities	120.8	114.4				
Short-term financial debt	12.8	10.3				
Other current liabilities	349.8	355.9				
Total equity and liabilities	984.4	986.9				





Earnings by divisions and BU





Software & Services


44.8 %

of H1 2025 revenue

€144.4m

H1 2025 revenue

Adj.EBIT €1.9m Adj.EBIT margin 1.3%



H1 2025 Adj.EBIT		Ope Inc	usted rating ome j.EBIT)		nge 2025 2024		j.EBIT argin
in million of euros	S	2025	2024	€m	%	2025	2024
Total Software & Services		1.9	(1.4)	+3.3	+233.6%	1.3%	-0.9%
Cegedi	m Santé	(3.2)	(1.6)	(1.6)	(100.1)%	(8.2)%	(4.1)%
Pharmacists ar	nce, HR, nd other services	6.7	3.4	3.3	+97.0%	7.6%	3.9%
International A	Activities	(1.6)	(3.2)	1.6	+51.4%	(8.5)%	(12.3)%

- Cegedim Santé: Cost management = stable EBITDA though R&D capitalization drop. Increase in R&D amortization: quicker and alignment to group policy for Visiodent
- Other activities in France: momentum in HR and Health Insurance activities (run of 2024 projects) in terms of revenue and profitability offsets the slowdown in pharmacist activity.
- International: improvement in profitability tanks to INPS exit




Flow

16.5%

of H1 2025 revenue H1 2025 revenue

€53.4m

Adj.EBIT €5.7m Adj.EBIT margin 10.7%





- Revenue growth of 7.8% thanks to e-business (digitalization of processes and exchange of dematerialized data) on its two segments and Third-party payer (strong growth in demand for its and investigation of long-term illness).
- Adjusted Operating Income slight decrease of 2.9% due to increase in expenses in the Invoicing and Purchasing segment in order to prepare for the entry into force of the reform on the dematerialization of invoices in France in 2026.





Data & Marketing


19.7 %

of H1 2025 revenue

€63.4m

H1 2025 revenue

Adj.EBIT €9.2m Adj.EBIT margin 14.6%





- Revenue up 6.9% across both businesses. Data (mainly in France) and Marketing (strong sales momentum with new and existing customers)
- Adjusted Operating Income up €4 million (+75.6%). Strong profitability in Data. Cost control and effective production tools for Marketing.




of H1 2025 revenue

H1 2025 revenue

€43.2m

Adj.EBIT €1.5m Adj.EBIT margin 3.5%





- Revenue up 8.1% thanks to both businesses. Insurance (dynamic overflow offering) and Business Services (attractive compliance offering)
- Adjusted Operating Income down slightly by €0.4 million (transfer of an HR BPO client to the Software solution)





Cloud & Support

5.6%

H1 2025 revenu

€18.2m

Adj.EBIT €0.1m Adj.EBIT margin 0.4%

H1 2025 €18.2m +0.3 % reported Revenue Cloud Support



- Revenue low growth of 0.3% due to the exepected non-renewal of a contract in Q2.
- Adjusted Operating Income returns to positive territory thanks to a €1.4 million increase resulting from cost structure optimization





Revenu by BU as of 30/06/2025

Health and Provident Insurance

Revenue = €83.6m +7.1% rep. •+7.0% LfL

- €31.1m +4.4%
- €21.3m +8.8%
- €31.2m +8.8%

Healthcare professionals

Revenue = €65.5m (16.6)% rep. • (9.5)% LfL

Cloud & Support

Revenue = €18.2m +0.3% rep. •+0.3% LfL

■ Software & Services ■ Flow ■ BPO

Cegedim Business Services*

Revenue = €91.8m +8.0% rep. •+8.0% LfL

- €47.8m +9.1%
- €32.1m +7.1%
- €12.0m +6.4%

* RH et e(business

Data & Marketing

Revenue = €63.4m +6.9% rep. • +6.8% LfL

- Data €28.7m +2.5 %
- Marketing €34.7m +10.8 %





Adjusted Operating Income by BU as of 30/06/2025

Health and Provident Insurance

Revenue = €163m

Adj.EBIT** = €5.6m (+9,0%)

Adj.EBIT** margin = 6.7 %

Healthcare Professionals

Revenue * = €158m

Adj.EBIT** = €(8.7)m (-5,0 %)

Adj.EBIT** margin = (13.3)%

Cloud & Support

Revenue * = €38m

Adj.EBIT** = $\{0.1\text{m} (+105,3\%)\}$

Adj.EBIT** margin = 0.4 %

Cegedim Business Services

Revenue * = €170m

Adj.EBIT** = €12.3m (+18,0%)

Adj.EBIT** margin = 13.4 %

Data & Marketing

Revenue * = €125.5m

Adj.EBIT** = **€9.2m** (+75,6%)

Adj.EBIT** margin = 14.6 %

18



^{*} Revenue

^{**} Adjusted EBIT



Outlook 2025



Revenue

Like-for-Like growth in a 2 % to 4% range



Recurring
Operating Income

Expected to increase

Disclosure: Based on currently available information. The Group does not provide earnings estimates or forecasts.





Financial agenda

2025

Septembre 26


SFAF meeting 10 am 2025

October 23

after the market closes

Third Quarter Revenue





Q & A



© Cegedim 2025 21



Appendix



© Cegedim 2025 22



P&L: Adjusted indicators

in million of euros	H1 2025	H1 2024	Change %	Change €
Operating income	9.5	7.7	22.4%	1.8
Other non-recurring operating income and expenses	(7.4)	(2.6)		
Other items affecting operating income	(1.6)			
Sub-total: specific items affecting operating income	(9.0)	(2.6)	243.6%	(6.4)
Operating income adjusted for specific items	18.5	10.3	78.4%	8.2
Depreciation and amortization expenses	(42.7)	(41.9)	2.1%	(0.8)
Adjusted EBITDA	61.2	52.2	17.2%	9.0

"Adjusted" indicators: As mandated by the new accounting standards that took effect in France on January 1, 2025 (Nouveau Plan Comptable Général), the Group only records a limited number of specific transactions in the non-recurring operating income and expenses line of its parent company financial statements. The approach is the same for the consolidated financial statements, with certain specific items for the fiscal year still recorded in the relevant lines under recurring operating income. Until 2024, these specific items were reported under other non-recurring operating income and expenses. As a result, 2025 "adjusted" indicators are comparable to the 2024 "recurring" indicators, allowing us to continue presenting our financial information using the same format.





Business Unites

Health and Provident Insurance

- Software for supplementary health and provident insurers
- Flow, Third party payment, outsourced management and other services

Healthcare Professionals

- Solutions for Doctors, Dentists, allied health Professionals, Pharmacists
- Telemedicine and appointments booking
- Medication and health products database

Cloud & Support

- Critical applications and **Health Data Hosting**
- IT services and cybersecurity

Cegedim Business Services

- Electronic Data Interchange
- Outsourced payroll and HR management

Data & Marketing

- Health data and analytics for the healthcare market
- Phygital Communication in healthcare
- E-promotion
- Storage and logistics of healthcare products



Merci pour votre attention

Pour plus d'informations Investors.relations@cegedim.com



www.cegedim.fr/finance









